Is Fezakinumab, an anti-IL22 antibody, a putative novel therapy for a subset of severe asthma? (2019)
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1183/13993003.congress-2019.oa1606
Publication URI: http://dx.doi.org/10.1183/13993003.congress-2019.oa1606
Type: Conference/Paper/Proceeding/Abstract